Feasibility of VATS(Video-Assisted Thoracoscopic Surgery) Lobectomy for Clinical Stage IB or II Non-Small Cell Lung Cancer
Video-assisted or minimally invasive surgery has become the standard approach for many
abdominal surgical operations such as cholecystectomy and fundoplication. With respect to
the thorax, video-assisted thoracoscopic surgery(VATS) is the accepted technique for biopsy
of the lung and pleura and surgical treatment of pneumothorax.Thoracoscopic, also termed
video-assisted thoracoscopic lobectomy has become accepted as a safe and effective procedure
to treat early-stage non-small cell lung cancer (NSCLC). Several pilot series of
thoracoscopic lobectomy in stage I lung cancer patients have been reported, demonstrating
low complication rates and effective short-term and long-term oncologic results. With
increasing experience, the indications for thoracoscopic lobectomy have been expanded.
Single and Multi-institutional studies have demonstrated that thoracoscopic lobectomy is not
only a safe and feasible technique, but is also associated with decreased morbidity,
including shorter length of hospitalization and chest tube duration, decreased postoperative
pain, improved preservation of pulmonary function, reduced inflammatory response as measured
by lower postoperative cytokine levels, and shorter recovery time, as compared with
conventional thoracotomy. The advantages of thoracoscopic lobectomy have been demonstrated
in patients with clinical stage I NSCLC, and this strategy has been found to be particularly
useful for specific subsets of patients such as the elderly and those patients with poor
performance status.
The purpose of this study is to know whether VATS lobectomy for clinical stage IB or II
non-small cell lung cancer is possible.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To examine the feasibility of VATS lobectomy for clinical stage IB or II non-small cell lung cancer.
Hyun-Sung Lee, MD, PhD
Principal Investigator
National Cancer Center, Korea
Korea: Food and Drug Administration
NCCCTS-06-223
NCT00425022
January 2007
Name | Location |
---|